Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
Johnson & Johnson earnings per share (EPS) for the twelve months ending Mar 11, 2025 was $6.7, a (52.0%) increase year-over-year.
As of Mar 11, 2025, Johnson & Johnson's P/E ratio is 28.3x. This is calculated by dividing the current share price of $165.9 by the Earnings per Share (EPS) for the trailing twelve months, which is $6.7. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
Johnson & Johnson is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $197.1, compared to a market price of around $165.9. This suggests a potential undervaluation of 18.9%.